Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database

This retrospective study estimated healthcare resource use (HRU), symptoms and toxicities (SxTox), and costs in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML), stratified by hematopoietic stem cell transplantation (HSCT) status. Claims data were used to identify adult patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Bhavik J., Chen, Chi-Chang, Medeiros, Bruno C., McGuiness, Catherine B., Wilson, Samuel, Horvath Walsh, L. Elise, Wade, Rolin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822861/
https://www.ncbi.nlm.nih.gov/pubmed/31222713
http://dx.doi.org/10.1007/s12325-019-01003-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822861/
https://www.ncbi.nlm.nih.gov/pubmed/31222713
http://dx.doi.org/10.1007/s12325-019-01003-7

Ejemplares similares